What is the unique status of hybrid capture NGS within the context of molecular target-driven therapy for solid tumors?

What is the unique status of hybrid capture NGS within the context of molecular target-driven therapy for solid tumors?

What is the unique status of hybrid capture NGS within the context of molecular target-driven therapy for solid tumors?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Nir Peled, MD, PhD, FCCP

Professor Nir Peled, MD, PhD, FCCP

Pulmonologist and Medical Oncologist
Thoracic Cancer Unit
Davidoff Cancer Center
Tiqwa, Israel